MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 465275 | Name: MAZ51

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MAZ51 is a VEGFR3 inhibitor. MAZ51 can suppress the activation of VEGFR3 induced by VEGF-C. However, it does not block VEGF-C-mediated VEGFR2 stimulation. In vitro and in vivo assays have shown that MAZ51 displays moderate antiproliferative activity and mediates cell apoptosis in multiple types of tumor cells.

Chemical Structure

MAZ51
MAZ51
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465275

Name: MAZ51

CAS#: unknown

Chemical Formula: C21H18N2O

Exact Mass: 314.1419

Molecular Weight: 314.39

Elemental Analysis: C, 80.23; H, 5.77; N, 8.91; O, 5.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MAZ51; MAZ 51; MAZ-51;
IUPAC/Chemical Name
(E)-3-((4-(dimethylamino)naphthalen-1-yl)methylene)indolin-2-one
InChi Key
VFCXONOPGCDDBQ-QGOAFFKASA-N
InChi Code
InChI=1S/C21H18N2O/c1-23(2)20-12-11-14(15-7-3-4-9-17(15)20)13-18-16-8-5-6-10-19(16)22-21(18)24/h3-13H,1-2H3,(H,22,24)/b18-13+
SMILES Code
CN(C)C1=C2C(C=CC=C2)=C(/C=C3C(NC4=C/3C=CC=C4)=O)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 314.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Park S, Kim HJ, Hwang HS, Han AR. Peptides Targeting Fms-Related Tyrosine Kinase-4 Activate the Function of Natural Killer Cells in Acute Myeloid Leukemia. Int J Stem Cells. 2021 Jun 30. doi: 10.15283/ijsc21083. Epub ahead of print. PMID: 34158419. 2: Yamamura A, Nayeem MJ, Muramatsu H, Nakamura K, Sato M. MAZ51 Blocks the Tumor Growth of Prostate Cancer by Inhibiting Vascular Endothelial Growth Factor Receptor 3. Front Pharmacol. 2021 Apr 20;12:667474. doi: 10.3389/fphar.2021.667474. PMID: 33959030; PMCID: PMC8093795. 3: Lv J, Yuan J, Xu CJ, Hao JQ, Qin YC, Wang XQ, Wang YF. VEGF-C/VEGFR-3/iNOS Signaling in Osteosarcoma MG63 Cells Mediates Stimulatory Effects on Human Umbilical Vein Endothelial Cell Proliferation. Chin Med Sci J. 2021 Mar 31;36(1):35-42. doi: 10.24920/003753. PMID: 33853707. 4: Li J, Chen Y, Zhang L, Xing L, Xu H, Wang Y, Shi Q, Liang Q. Total saponins of panaxnotoginseng promotes lymphangiogenesis by activation VEGF-C expression of lymphatic endothelial cells. J Ethnopharmacol. 2016 Dec 4;193:293-302. doi: 10.1016/j.jep.2016.08.032. Epub 2016 Aug 21. PMID: 27553977; PMCID: PMC5108701. 5: Lee JY, Hong SH, Shin M, Heo HR, Jang IH. Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels. Biochem Biophys Res Commun. 2016 Sep 16;478(2):733-8. doi: 10.1016/j.bbrc.2016.08.017. Epub 2016 Aug 6. PMID: 27507214. 6: Lim J, Ryu JH, Kim EJ, Ham S, Kang D. Inhibition of Vascular Endothelial Growth Factor Receptor 3 Reduces Migration of Gastric Cancer Cells. Cancer Invest. 2015;33(8):398-404. doi: 10.3109/07357907.2015.1047509. Epub 2015 Jun 26. PMID: 26115478. 7: Al-Husseini A, Kraskauskas D, Mezzaroma E, Nordio A, Farkas D, Drake JI, Abbate A, Felty Q, Voelkel NF. Vascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertension. Pulm Circ. 2015 Mar;5(1):101-16. doi: 10.1086/679704. PMID: 25992275; PMCID: PMC4405722. 8: Park JH, Shin YJ, Riew TR, Lee MY. The indolinone MAZ51 induces cell rounding and G2/M cell cycle arrest in glioma cells without the inhibition of VEGFR-3 phosphorylation: involvement of the RhoA and Akt/GSK3β signaling pathways. PLoS One. 2014 Sep 30;9(9):e109055. doi: 10.1371/journal.pone.0109055. PMID: 25268128; PMCID: PMC4182637. 9: Lee JY, Park S, Kim DC, Yoon JH, Shin SH, Min WS, Kim HJ. A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia. J Clin Immunol. 2013 May;33(4):826-37. doi: 10.1007/s10875-013-9877-2. Epub 2013 Feb 13. PMID: 23404187. 10: Kazenwadel J, Secker GA, Betterman KL, Harvey NL. In vitro assays using primary embryonic mouse lymphatic endothelial cells uncover key roles for FGFR1 signalling in lymphangiogenesis. PLoS One. 2012;7(7):e40497. doi: 10.1371/journal.pone.0040497. Epub 2012 Jul 6. PMID: 22792354; PMCID: PMC3391274. 11: Matsuura M, Onimaru M, Yonemitsu Y, Suzuki H, Nakano T, Ishibashi H, Shirasuna K, Sueishi K. Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol. 2009 Oct;175(4):1709-21. doi: 10.2353/ajpath.2009.081139. Epub 2009 Sep 24. PMID: 19779139; PMCID: PMC2751566. 12: Lin CI, Chen CN, Huang MT, Lee SJ, Lin CH, Chang CC, Lee H. Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells. Cell Mol Life Sci. 2008 Sep;65(17):2740-51. doi: 10.1007/s00018-008-8314-9. PMID: 18642114. 13: Ny A, Koch M, Vandevelde W, Schneider M, Fischer C, Diez-Juan A, Neven E, Geudens I, Maity S, Moons L, Plaisance S, Lambrechts D, Carmeliet P, Dewerchin M. Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood. 2008 Sep 1;112(5):1740-9. doi: 10.1182/blood-2007-08-106302. Epub 2008 May 12. PMID: 18474726. 14: Breslin JW, Yuan SY, Wu MH. VEGF-C alters barrier function of cultured lymphatic endothelial cells through a VEGFR-3-dependent mechanism. Lymphat Res Biol. 2007;5(2):105-13. doi: 10.1089/lrb.2007.1004. PMID: 17935478; PMCID: PMC3001341. 15: Breslin JW, Gaudreault N, Watson KD, Reynoso R, Yuan SY, Wu MH. Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H709-18. doi: 10.1152/ajpheart.00102.2007. Epub 2007 Mar 30. PMID: 17400713. 16: Foster RR, Satchell SC, Seckley J, Emmett MS, Joory K, Xing CY, Saleem MA, Mathieson PW, Bates DO, Harper SJ. VEGF-C promotes survival in podocytes. Am J Physiol Renal Physiol. 2006 Jul;291(1):F196-207. doi: 10.1152/ajprenal.00431.2005. Epub 2006 Mar 8. PMID: 16525158. 17: Kirkin V, Thiele W, Baumann P, Mazitschek R, Rohde K, Fellbrich G, Weich H, Waltenberger J, Giannis A, Sleeman JP. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int J Cancer. 2004 Dec 20;112(6):986-93. doi: 10.1002/ijc.20509. PMID: 15386354.